RecruitingPhase 3NCT06238622
A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast
Studying Idiopathic pulmonary fibrosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Boehringer Ingelheim
- Intervention
- Nerandomilast(drug)
- Enrollment
- 1700 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2024 – 2027
Study locations (30)
- University of Alabama at Birmingham, Birmingham, Alabama, United States
- University of Arizona, Tucson, Arizona, United States
- University of Southern California, Los Angeles, California, United States
- Cedars-Sinai Medical Center, Los Angeles, California, United States
- University of California Los Angeles, Los Angeles, California, United States
- University of California Davis, Sacramento, California, United States
- National Jewish Health, Denver, Colorado, United States
- Yale University School of Medicine, New Haven, Connecticut, United States
- Christiana Hospital, Newark, Delaware, United States
- Georgetown University, Washington D.C., District of Columbia, United States
- St. Francis Medical Institute, Clearwater, Florida, United States
- University of Florida, Gainesville, Florida, United States
- Clinical Research Specialists LLC - Kissimmee, Kissimmee, Florida, United States
- Advanced Pulmonary Research Institute, Loxahatchee Groves, Florida, United States
- Piedmont Physicians Pulmonary & Sleep Medicine of Buckhead, Atlanta, Georgia, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06238622 on ClinicalTrials.govOther trials for Idiopathic pulmonary fibrosis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT05988463Dose-Escalation Study of Artesunate Patients With IPFJoseph C. Wu
- RECRUITINGPHASE2NCT07572383Advanced Imaging to Assess the Effect of Immunosuppression on Progressive FibrosisPeter Caravan
- RECRUITINGNANCT07486206Optimizing the Follow-Up Journey in Interstitial Lung Disease: The OPTIMIZE-ILD-2 TrialHospital de Granollers
- RECRUITINGNANCT07482917Optimizing the Diagnostic Journey in Interstitial Lung Disease: The OPTIMIZE-ILD-1 TrialHospital de Granollers
- RECRUITINGPHASE2NCT06241560A Study in People With Idiopathic Pulmonary Fibrosis to Test Whether Pirfenidone Influences the Amount of BI 1015550 in the BloodBoehringer Ingelheim
- RECRUITINGPHASE3NCT07201922A Study to Test Whether Nerandomilast Can Help Slow Down Changes in the Lung in People With a Family History of Pulmonary FibrosisBoehringer Ingelheim
- RECRUITINGPHASE2NCT06968845A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary FibrosisRein Therapeutics
- ENROLLING BY INVITATIONNCT06885515Telomeres Length in Israeli Fibrotic ILD PatientsBarzilai Medical Center